このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Initiator Pharma マネジメント

マネジメント基準チェック /24

Initiator Pharma'sの CEO はClaus Olesenで、 May2016年に任命され、の在任期間は 8.08年です。は、会社の株式の4.3%を直接所有しており、その価値はSEK 23.20M 。経営陣と取締役会の平均在任期間はそれぞれ8.3年と5.6年です。

主要情報

Claus Olesen

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	8.1yrs
CEOの所有権	4.3%
経営陣の平均在職期間	8.3yrs
取締役会の平均在任期間	5.6yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Claus Olesen (50 yo)

8.1yrs

在職期間

Dr. Claus Elsborg Olesen is Chief Executive Officer at Stipe Therapeutics. He serves Chief Executive Officer at Initiator Pharma A/S since May 02, 2016 and serves as its Director since September 19, 2016 a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Claus Olesen	Co-Founder	8.1yrs	データなし	4.3% DKK 22.3m
Dan Peters	Co-Founder & CTO	8.4yrs	データなし	データなし
Ulf Simonsen	Co-Founder	no data	データなし	1.23% DKK 6.4m
Mikael Thomsen	Co-Founder & Chief Development Officer	no data	データなし	1.42% DKK 7.4m
Torgeir Vaage	Chief Financial Officer	8.4yrs	データなし	データなし
Allan Wehnert	Senior Vice President of Clinical and R&D Strategy & Portfolio Management	3.5yrs	データなし	データなし
Susanne Thomsen	Head of Clin Ops	no data	データなし	データなし
Rene Egebro	Head of CMC	no data	データなし	データなし

8.3yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: INITの経営陣は経験豊富で経験豊富です（平均在職期間は8.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Claus Olesen	Co-Founder	7.8yrs	データなし	4.3% DKK 22.3m
Gunnar Magnus Severus Persson	Chairman of the Board of Directors	7.8yrs	データなし	0.50% DKK 2.6m
Henrik Moltke	Director	7.8yrs	データなし	0.26% DKK 1.4m
Irwin Goldstein	Member of Scientific & Clinical Advisory Board	3.5yrs	データなし	データなし
Gunilla Ekstrom	Independent Director	1.7yrs	データなし	0.036% DKK 186.2k
Annette Colin	Director	3.4yrs	データなし	0.75% DKK 3.9m
Peter Holm	Director	7.8yrs	データなし	データなし
Sue Goldstein	Member of Scientific & Clinical Advisory Board	3.5yrs	データなし	データなし

5.6yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: INITの取締役会は経験豊富であると考えられます ( 5.6年の平均在任期間)。

Initiator Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

No independent directors

No independent directors

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Announces Management Changes

Recent updates

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24